18F-FDG-PET in patients with malignant lymphoma having long-term follow-up: Staging and restaging, and evaluation of treatment response and recurrence

Annals of Nuclear Medicine

Volumn 22, Issue 9, 2008, Pages 795-802

  Isohashi, Kayako ^a   Tatsumi, Mitsuaki ^a   Higuchi, Ichiro ^a   Inoue, Atsuo ^a   Nakajo, Kazuya ^a   Ishikawa, Jun ^a   Shimosegawa, Eku ^a   Kanakura, Yuzuru ^a   Nakamura, Hironobu ^a   Hatazawa, Jun ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

FDG; Fluorodeoxyglucose; Malignant lymphoma; PET; Treatment response

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; APPARATUS; ARTICLE; CANCER RECURRENCE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; FEMALE; FOLLOW UP; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TREATMENT OUTCOME; WHOLE BODY PET; ADOLESCENT; LONGITUDINAL STUDY; METHODOLOGY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TUMOR RECURRENCE;

ADOLESCENT; ADULT; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; LYMPHOMA; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 57049137272     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12149-008-0186-4     Document Type: Article

References (36)

1. G.K. von Schulthess H.C. Steinert T.F. Hany 2006 Integrated PET/CT: current applications and future directions Radiology 238 405 422
2. M. Tatsumi C. Cohade Y. Nakamoto E.K. Fishman R.L. Wahl 2005 Direct comparison of FDG PET and CT findings in patients with lymphoma: initial experience Radiology 237 1038 1045
3. N.G. Mikhaeel 2006 Use of FDG-PET to monitor response to chemotherapy and radiotherapy in patients with lymphomas Eur J Nucl Med Mol Imaging 33 22 26
4. F. Moog M. Bangerter C.G. Diederichs A. Guhlmann E. Merkle N. Frickhofen 1998 Extranodal malignant lymphoma: detection with FDG PET versus CT Radiology 206 475 481
5. K.D. Stumpe M. Urbinelli H.C. Steinert C. Glanzmann A. Buck G.K. von Schulthess 1998 Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography Eur J Nucl Med Mol Imaging 25 721 728
6. J.S. Newman I.R. Francis M.S. Kaminski R.L. Wahl 1994 Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-d-glucose: correlation with CT Radiology 190 111 116
7. R. Thill J. Neureburg U. Fabry U. Cremerius G. Wagenknecht D. Hellwig 1997 Comparison of findings with 18-FDG PET and CT in pretherapeutic staging of malignant lymphoma Nuklearmedizin 36 234 239
8. I. Buchmann M. Reinhardt K. Elsner D. Bunjes C. Altehoefer J. Finke 2001 2-(fluorine-18)fluoro-2-deoxy-d-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial Cancer 91 889 899
9. 18F-2- deoxy-2-fluoro-d-glucose positron emission tomography in the staging and restaging of patients with lymphoma Cancer 104 1066 1074
10. L.S. Freudenberg G. Antoch P. Schütt T. Beyer W. Jentzen S.P. Müller 2004 FDG-PET/CT in re-staging of patients with lymphoma Eur J Nucl Med Mol Imaging 31 325 329
11. J.N. Talbot C. Haioun J.D. Rain M. Meignan M. Wioland J.L. Misset 2001 [18F]-FDG positron imaging in clinical management of lymphoma patients Crit Rev Oncol Hematol 38 193 221
12. K. Spaepen S. Stroobants P. Dupont S. Van Steenweghen J. Thomas P. Vandenberghe 2001 Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 19 414 419
13. H. Iida S. Miura Y. Shoji T. Ogawa H. Kado Y. Narita 1998 Noninvasive quantitation of cerebral blood flow using oxygen-15-water and a dual-PET system J Nucl Med 39 1789 1798
14. M.E. Juweid S. Stroobants O.S. Hoekstra F.M. Mottaghy M. Dietlein A. Guermazi 2007 Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma J Clin Oncol 25 571 578
15. B.D. Cheson B. Pfistner M.E. Juweid R.D. Gascoyne L. Specht S.J. Horning 2007 Revised response criteria for malignant lymphoma J Clin Oncol 25 579 586
16. R.E. Dorfman M.B. Alpern B.H. Gross M.A. Sandler 1991 Upper abdominal lymph nodes: criteria for normal size determined with CT Radiology 180 319 322
17. G.M. Glazer B.H. Gross L.E. Quint I.R. Francis F.L. Bookstein M.B. Orringer 1985 Normal mediastinal lymph nodes: number and size according to American Thoracic Society mapping Am J Roentgenol 144 261 265
18. T.A. Lister D. Crowther S.B. Sutcliffe E. Glatstein G.P. Canellos R.C. Young 1989 Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting J Clin Oncol 7 1630 1636
19. B.D. Cheson S.J. Horning B. Coiffier M.A. Shipp R.I. Fisher J.M. Connors 1999 Report of an international workshop to standardise response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group J Clin Oncol 17 1244 1253
20. M.E. Juweid G.A. Wiseman J.M. Vose J.M. Ritchie Y. Menda J.E. Wooldridge 2005 Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography J Clin Oncol 23 4652 4661
21. U. Cremerius U. Fabry U. Kröll M. Zimny J. Neuerburg R. Osieka 1999 Clinical value of FDG PET for therapy monitoring of malignant lymphoma: results of a retrospective study in 72 patients Nuklearmedizin 38 24 30
22. G. Juweid Y. Beguin F. Najjar R. Hustinx M.F. Fassotte P. Rigo 2001 Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low grade non-Hodgkin's lymphoma (NHL) Ann Oncol 12 825 830
23. R.L. Wahl K. Zasadny M. Helvie G.D. Hutchins B. Weber R. Cody 1993 Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation J Clin Oncol 11 2101 2111
24. G.P. Canellos 1988 Residual mass in lymphoma may not be residual disease J Clin Oncol 6 931 933
25. G. Jerusalem Y. Beguin M.F. Fassotte F. Najjar P. Paulus P. Rigo 1999 Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging Blood 94 429 433
26. L. Kostakoglu S.J. Goldsmith 2000 Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: is it time to shift gears? Eur J Nucl Med Mol Imaging 27 1564 1578
27. R. Kumar I. Maillard S.J. Schuster A. Alavi 2004 Utility of fluorodeoxyglucose-PET imaging in the management of patients with Hodgkin's and non-Hodgkin's lymphomas Radiol Clin North Am 42 1083 1100
28. W.C. Lavely D. Delbeke J.P. Greer D.S. Morgan D.W. Byrne R.R. Price 2003 FDG PET in the follow-up management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after first-line chemotherapy Int J Radiat Oncol Biol Phys 57 307 315
29. G. Jerusalem V. Warland F. Najjar P. Paulus M.F. Fassotte G. Fillet 1999 Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma Nucl Med Commun 20 13 20
30. U. Cremerius U. Fabry J. Neuerburg M. Zimny R. Osieka U. Buell 1998 Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma Nucl Med Commun 19 1055 1063
31. L. Specht 2007 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas Semin Radiat Oncol 17 190 197
32. R.T. Hoppe R.H. Advani P.J. Bierman C.D. Bloomfield F. Buadi B. Djulgegovic 2006 Hodgkin disease/lymphoma. Clinical practice guidelines in oncology J Natl Compr Canc Netw 4 210 230
33. A.D. Zelenetz R.H. Advani F. Buadi F. Cabanillas M.A. Caligiuri M.S. Czuczman 2006 Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology J Natl Compr Canc Netw 4 258 310
34. M. Hoffmann S. Wöhrer A. Becherer A. Chott B. Streubel K. Kletter 2006 18F-Fluoro-deoxy-glucose positron emission tomography in lymphoma of mucosa-associated lymphoid tissue: histology makes the difference Ann Oncol 17 1761 1765
35. K. Enomoto K. Hamada H. Inohara I. Higuchi Y. Tomita T. Kubo 2008 Mucosa-associated lymphoid tissue lymphoma studied with FDG-PET: a comparison with CT and endoscopic findings Ann Nucl Med 22 261 267
36. N.G. Schaefer T.F. Hany N.G. Schaefer T.F. Hany C. Taverna B. Seifert 2004 Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging-do we need contrast-enhanced CT? Radiology 232 823 829